Movement Alert|GeneDx Holdings Intraday Rise 5.51% in Regular Trading, Broker Maintains Buy After Quarterly Results

Market Focus11-11

On November 11, GeneDx Holdings rose 5.51% in Regular Trading, trading near $58.25 per share, with turnover of $6.7877 million.

The clearest catalyst in recent public disclosures was post-earnings analyst support: Piper Sandler maintained a Buy rating with a $95 price target, while BTIG also kept its Buy rating, though it lowered its target to $85 from $90.

That followed GeneDx Holdings reporting quarterly adjusted EPS of $0.28, above the $0.07 consensus estimate, on revenue of $123.1 million versus expectations of $122.9 million. Revenue guidance for Q4 was $135 million, below the $142.6 million consensus, while the company reiterated full-year revenue guidance of $475 million to $490 million. The mixed print helps explain why rating support, rather than the earnings release alone, appears most relevant to the latest rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment